Phil Noland Roberts - 13 Dec 2023 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting relationship: Chief Technology Officer
Issuer ticker: IMNM
Reported as of: 13 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Dec 2023, 19:28:11 UTC
Prior SEC filing: 15 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Sandra Stoneman, Attorney-in-fact

Key filing fact

Phil Noland Roberts filed Form 4 for Immunome Inc. (IMNM) on 15 Dec 2023.

Key facts

This page summarizes Phil Noland Roberts's Form 4 filing for Immunome Inc. (IMNM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Dec 2023, 19:28.

Change

Previous filing in this sequence was filed on 15 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNM transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +275,000
Change %
Price: $0.000000
Shares after: 275,000
Date: 13 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 275,000
Exercise price: $7.34
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the options vest on December 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.